CRIS Stock Overview
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Curis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.00 |
| 52 Week High | US$17.49 |
| 52 Week Low | US$3.80 |
| Beta | 3.35 |
| 11 Month Change | -2.76% |
| 3 Month Change | -46.14% |
| 1 Year Change | -48.72% |
| 33 Year Change | -96.27% |
| 5 Year Change | -84.29% |
| Change since IPO | -99.75% |
Recent News & Updates
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Aug 07
Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
Aug 05Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Aug 07Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
Aug 05Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 03Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry
Dec 26We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate
Nov 03We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
Aug 05Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Apr 19Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?
Jan 02Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Sep 16Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study
Aug 18Curis: Asymmetric Risk And Reward
Jul 17Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation
Mar 28Checking In On Curis
Dec 15Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth
Dec 04We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth
Aug 29Curis Inc.: Revisiting CA-4948 After Q2 Update
Aug 25Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33
Mar 19Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year
Feb 17
Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition
Dec 23Curis prices equity offering at $5.75/share
Dec 09Shareholder Returns
| CRIS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 42.5% | 4.7% | 3.1% |
| 1Y | -48.7% | 15.1% | 24.9% |
Return vs Industry: CRIS underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: CRIS underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| CRIS volatility | |
|---|---|
| CRIS Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CRIS's share price has been volatile over the past 3 months.
Volatility Over Time: CRIS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 49 | Jim Dentzer | www.curis.com |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
Curis, Inc. Fundamentals Summary
| CRIS fundamental statistics | |
|---|---|
| Market cap | US$26.31m |
| Earnings (TTM) | -US$47.57m |
| Revenue (TTM) | US$10.16m |
3.5x
P/S Ratio-0.8x
P/E RatioIs CRIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRIS income statement (TTM) | |
|---|---|
| Revenue | US$10.16m |
| Cost of Revenue | US$40.39m |
| Gross Profit | -US$30.23m |
| Other Expenses | US$17.35m |
| Earnings | -US$47.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.96 |
| Gross Margin | -297.48% |
| Net Profit Margin | -468.18% |
| Debt/Equity Ratio | -5,527.2% |
How did CRIS perform over the long term?
See historical performance and comparison